menu
    • menu

    Company profile for OncXerna Therapeutics

    NEW Drugs in Dev: 3
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Existing precision medicines target just 10 percent of cancers – those with gene mutations or oncogenic drivers for a small number of genes. OncXerna Therapeutics is ushering in a new era of precision medicine, leveraging the company’s deep understanding of tumor biology at the RNA level to deliver more effective therapies for many more patients. OncXerna applies its understanding of RNA signatures to describe the dominant...
    Existing precision medicines target just 10 percent of cancers – those with gene mutations or oncogenic drivers for a small number of genes. OncXerna Therapeutics is ushering in a new era of precision medicine, leveraging the company’s deep understanding of tumor biology at the RNA level to deliver more effective therapies for many more patients. OncXerna applies its understanding of RNA signatures to describe the dominant biology of the patient’s cancer and match it to therapies with mechanisms that modify the dominant biology to dramatically improve patient outcomes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OncXerna TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    300 Fifth Avenue Suite 6040 Waltham, MA 02451
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://oncxerna.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncxernatherapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OncXerna Announces Final Results from PII Trial of Bavituximab & Pembrolizumab
    OncXerna Announces Final Results from PII Trial of Bavituximab & Pembrolizumab

    23 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/01/23/2593058/0/en/OncXerna-Therapeutics-Announces-Final-Results-and-New-Xerna-TME-Panel-Biomarker-Data-from-a-Phase-2-Trial-of-Bavituximab-Plus-Pembrolizumab-in-Patients-with-Previously-Untreated-Ad.html

    GLOBENEWSWIRE
    23 Jan 2023
    Share Share
    OncXerna Therapeutics Announces New Xerna™ TME Panel Biomarker Data
    OncXerna Therapeutics Announces New Xerna™ TME Panel Biomarker Data

    12 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/12/2513841/0/en/OncXerna-Therapeutics-Announces-New-Xerna-TME-Panel-Biomarker-Data-from-Retrospective-Analysis-of-Results-from-a-Randomized-Phase-2-Trial-Evaluating-Anti-PD-1-Maintenance-Therapy-i.html

    GLOBENEWSWIRE
    12 Sep 2022
    Share Share
    OncXerna doses first subject to evaluate navicixizumab in Phase II trial
    OncXerna doses first subject to evaluate navicixizumab in Phase II trial

    09 Sep 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/oncxerna-subject-navicixizumab-trial/

    CLINICALTRIALSARENA
    09 Sep 2022
    Share Share
    OncXerna Therapeutics Doses First Patient in Ph2 Trial Evaluating Navicixizumab
    OncXerna Therapeutics Doses First Patient in Ph2 Trial Evaluating Navicixizumab

    08 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/08/2512403/0/en/OncXerna-Therapeutics-Doses-First-Patient-in-Phase-2-Trial-Evaluating-Navicixizumab-Alone-or-in-Combination-with-Chemotherapy-in-Patients-with-Select-Advanced-Solid-Tumors.html

    GLOBENEWSWIRE
    08 Sep 2022
    Share Share
    OncXerna's Upcoming ASCO Poster Featuring Data of PII Glioblastoma Trial
    OncXerna's Upcoming ASCO Poster Featuring Data of PII Glioblastoma Trial

    03 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/03/2455957/0/en/OncXerna-Therapeutics-Announces-Upcoming-ASCO-Poster-Featuring-Data-Showing-the-Phase-2-Glioblastoma-Trial-of-Bavituximab-with-Chemoradiation-and-Adjuvant-Temozolomide-Met-its-Prim.html

    GLOBENEWSWIRE
    03 Jun 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search